Biohaven Investor Event at AAN

Los Angeles, CA (near convention center), April 22, 2018

Biohaven Investor Event at AAN
KOL Presentation and Fireside Chat

Date: Sunday, April 22nd, 2018
Time: 6-7:30pm
Location: Los Angeles, CA (near convention center)

Rimegepant New Phase 3 Data: Single Dose Durable Headache Relief and Recovery of Function Endpoints
Pivotal trial data presentation by Dr. Richard Lipton followed by migraine expert fireside chat

Migraine Expert Fireside Chat Participants:

PETER GOADSBY MD PhD
King’s College London
Prof of Experimental Med & Therapeutics/Director of WTCR
Basic and Clinical Neuroscience
Clinical Neurosciences Clinical Academic Group

DAVID DODICK MD
David W. Dodick
Professor
Department of Neurology
Mayo Clinic Arizona

RICHARD B. LIPTON, MD
Edwin S. Lowe Professor and Vice Chair of Neurology
Professor of Epidemiology and Population Health
Professor of Psychiatry and Behavioral Science
Director, Division of Cognitive Aging and Dementia
Director, Montefiore Headache Center
Albert Einstein College Of Medicine

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Biohaven Pharmaceuticals, Inc [BHVN] US$2,045 MM MCap
Pre­sent­ed ex­pand­ed da­ta at AHS (Ju­ly 2019) /dosed 1,780+ pa­tients (com­bined ex­po­sure of 105k dos­es) and ex­pand­ed safe­ty & pre­lim pre­ven­tive ef­fi­ca­cy da­ta (May 2019) from long-term safe­ty study. Up­com­ing mile­s­tones: Ph 3 to­p­line da­ta in pre­ven­tive treat­ment of mi­graine (rimege­pant) & Ph 2/3 to­p­line ef­fi­ca­cy & safe­ty in in­tra­nasal (BHV-3500) for acute treat­ment of mi­graine in 4Q19. [more in­for­ma­tion]

Event Contact

Brian Korb
Solebury Trout